PhytoGaia, a leading supplier and innovator in palm-derived phytonutrients, is pleased to announce the approval of a new and exciting human clinical trial evaluating its branded offering – STGaia® – for its role in healthy aging, telomere preservation, and cellular longevity.
The trial – titled “Plant Squalene and Tocotrienols Complex in Aging: Exploring Their Role in Telomere Preservation and Cellular Longevity” – is designed in collaboration with the prestigious Monash University Malaysia. This initiative underscores PhytoGaia’s continued commitment to investing in human-based research and scientific discovery in the field of healthy aging.
This randomized, double-blind, placebo-controlled clinical trial will involve healthy participants aged 50–75, with a study duration of six months. The primary objective is to investigate the impact of STGaia® on telomere length and telomerase activity, two well-established biomarkers of biological aging. Secondary endpoints include NAD+/NADH ratio, ATP levels, antioxidant enzyme activity, inflammation markers (e.g., CRP, TNF-α), and the expression of genes linked to cellular longevity, such as SIRT1, CDKN2A/p16, and IGF-1.
STGaia® is PhytoGaia’s new and novel proprietary, patent-pending complex of full-spectrum tocotrienols and plant squalene naturally extracted from palm fruits in their natural ratio and composition. Designed to address both visible and systemic aspects of aging, STGaia® is already featured in commercial products worldwide, supporting skin health, hair vitality, cognitive function, emotional resilience, and overall healthy aging.
“With the recent publication of a clinical study on full-spectrum palm tocotrienols (TocoGaia®) in healthy aging¹, this new trial with STGaia® marks an exciting next chapter in our ongoing exploration of palm phytonutrients and their role in cellular health and longevity,” said Mr. Bryan See, Vice President of PhytoGaia. “It underscores our continued commitment to human clinical research in aging and longevity. We’re proud to collaborate once again with Monash University – one of the world’s top academic institutions – as we investigate STGaia®’s potential in preserving telomere length and supporting genomic integrity at the cellular level.”
Prof. Dr. Ammu Radhakrishnan, Principal Investigator at Monash University Malaysia, added: “This study represents an exciting opportunity to investigate how our local naturally derived bioactives such as tocotrienols and squalene may modulate cellular aging pathways. We look forward to this collaboration to explore the potential of STGaia® to support genomic stability, telomere health, and overall longevity through a rigorous, science-based approach.”
Dr. Ariati Aris, Scientific Affairs Specialist at PhytoGaia, also commented: “Building on current scientific findings, we believe that the synergy between tocotrienols and plant squalene represents a novel approach to healthy aging. This trial will deepen our understanding of the mechanisms behind STGaia®’s multi-targeted benefits and further strengthen its clinical validation in longevity and healthy lifespan solutions.”
Participant recruitment is anticipated to begin soon with findings to be submitted for peer-reviewed publication and shared across global scientific and wellness communities. Brands, researchers, and industry partners interested in collaboration or updates on the trial can contact PhytoGaia directly.
For more information about PhytoGaia and our products, please visit www.PhytoGaia.com or contact info@PhytoGaia.com.
Disclaimer: The statements in the above article have not been evaluated by the Food and Drug Administration. They are not intended to diagnose, treat, cure or prevent any disease.
Reference:
-
Sharif R, Wai MK, Choon OT, Abdul Hafid SR, Lee TY. Tocotrienol-Enriched Beverage Enhances Psychological Well-Being, Antioxidant Defense, and Genomic Stability in Older Adults: A Randomized Controlled Trial. Nutrients. 2025 Jun 30;17(13):2179.
